Nicotinamide adenine dinucleotide (NAD+) is one of the most fundamental coenzymes in cellular biology — present in every living cell and essential for the oxidation-reduction reactions that drive ATP production through the electron transport chain. Beyond its classical role in energy metabolism, NAD+ serves as the obligate substrate for a class of regulatory enzymes — including the sirtuin deacylases, poly-ADP-ribose polymerases (PARPs), and CD38/CD157 glycohydrolases — that govern aging biology, DNA repair, inflammation, and circadian rhythm regulation. The age-related decline in cellular NAD+ levels has made NAD+ biology one of the most active areas of longevity and metabolic research over the past two decades.
For researchers investigating mitochondrial function, sirtuin-dependent aging pathways, DNA damage response, or the metabolic consequences of NAD+ repletion, direct NAD+ supplementation and its precursors represent a rich and expanding area of study with translational implications across multiple disease areas.
NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a dinucleotide consisting of adenosine monophosphate linked by a pyrophosphate bridge to nicotinamide mononucleotide. It exists in cells in both the oxidized (NAD+) and reduced (NADH) forms, interconverting as it accepts and donates electrons in metabolic reactions. The NAD+/NADH ratio is a direct reflection of cellular redox state and metabolic activity — a central readout in research on cellular bioenergetics.
NAD+ is biosynthesized through multiple pathways: the Preiss-Handler pathway (from nicotinic acid), the de novo synthesis pathway (from tryptophan), and the salvage pathway (from nicotinamide riboside [NR] or nicotinamide mononucleotide [NMN]). The salvage pathway is the primary route of NAD+ regeneration in most mammalian tissues and is the pathway targeted by most NAD+ precursor supplementation strategies.
For research purposes, NAD+ is supplied as the sodium salt form — a white to off-white hygroscopic powder — and requires careful handling to prevent oxidative degradation and moisture-induced hydrolysis.
| Property | Value |
|---|---|
| Full name | Nicotinamide adenine dinucleotide (oxidized form) |
| Also known as | NAD+, Coenzyme I, DPN+ |
| Molecular formula | C₂₁H₂₇N₇O₁₄P₂ |
| Molecular weight | 663.43 g/mol (free acid) |
| CAS number | 53-84-9 |
| Purity (Official Peptides) | ≥98% by HPLC |
| Physical form | White to off-white hygroscopic powder |
| Solubility | Freely water soluble |
| Storage (powder) | –20°C (long-term); 2–8°C (short-term, <30 days) |
| Storage (solution) | Prepare fresh; avoid prolonged storage in solution |
Sirtuins (SIRT1–SIRT7) are NAD+-dependent deacylase enzymes that remove acetyl and acyl groups from lysine residues on target proteins, regulating a wide range of cellular processes including metabolism, stress response, inflammation, and DNA repair. All seven sirtuins require NAD+ as an obligate co-substrate — consumed rather than catalytically recycled — meaning that sirtuin activity is directly limited by cellular NAD+ availability.
The connection between NAD+ decline, sirtuin inactivation, and aging phenotypes has been extensively examined in model organisms and human cells. Research has demonstrated that age-related NAD+ decline in mammals is associated with reduced SIRT1 and SIRT3 activity — two sirtuins with well-documented roles in mitochondrial biogenesis, fatty acid oxidation, and oxidative stress resistance. Studies restoring NAD+ levels through precursor supplementation (NMN, NR) have documented SIRT1 reactivation and partial reversal of aging-associated phenotypes in aged rodent models, establishing the NAD+/sirtuin axis as a tractable target in aging research.
Direct NAD+ research, as distinct from precursor research, examines the effects of increasing cellular NAD+ availability on sirtuin substrate acetylation status, downstream pathway activation (including PGC-1α-driven mitochondrial biogenesis and FOXO transcription factor deacetylation), and functional outcomes in metabolic and aging models.
NAD+ is the primary electron acceptor in glycolysis, the TCA cycle, and beta-oxidation, collecting electrons as NADH for delivery to Complex I of the mitochondrial electron transport chain. The availability of NAD+ to accept electrons from these catabolic pathways is rate-limiting for metabolic flux — when cellular NAD+ is depleted, these pathways stall, impairing ATP production and driving cells toward less efficient anaerobic metabolism.
Research has examined NAD+ supplementation in models of mitochondrial dysfunction, including disease models of Complex I deficiency, ischemia-reperfusion injury, and metabolic stress. Studies have reported improvements in mitochondrial membrane potential, respiratory complex activity, and ATP production in NAD+-supplemented cells and tissues. SIRT3 — the primary mitochondrial sirtuin — is considered a key mediator of these effects, as NAD+-driven SIRT3 activation deacetylates and activates multiple metabolic enzymes in the mitochondrial matrix.
PARP enzymes (poly-ADP-ribose polymerases) are major consumers of cellular NAD+ during DNA damage responses. When DNA strands are broken, PARP1 is activated and rapidly consumes large amounts of NAD+ to synthesize poly-ADP-ribose chains that mark damaged chromatin and recruit repair machinery. Paradoxically, this PARP-driven NAD+ consumption can further compromise cell viability during extensive DNA damage — depleting NAD+ below levels needed for ATP production and creating a futile death cycle.
Research examining NAD+ biology in DNA repair contexts has investigated how NAD+ availability modulates PARP1 activity, the efficiency of base excision repair, and cell survival following genotoxic challenge. Studies in cancer biology have examined the relationship between NAD+ levels and sensitivity to PARP inhibitor drugs. In aging research, the chronic low-level DNA damage that accumulates with age — and the continuous PARP activation it drives — is considered a major contributor to age-related NAD+ depletion, creating a research connection between genomic integrity and metabolic aging.
NAD+ levels oscillate with circadian rhythm, peaking during the active phase and falling during rest — an oscillation driven in part by the circadian regulation of NAMPT (the rate-limiting enzyme in NAD+ salvage synthesis). This circadian NAD+ rhythm is coupled to SIRT1 activity, creating a feedback loop between the molecular clock and metabolic regulation. Research has examined how disruption of this NAD+ circadian oscillation — through aging, shift work models, or genetic manipulation of clock genes — affects metabolic phenotypes in animal models.
Studies using timed NAD+ precursor supplementation have investigated whether restoring circadian NAD+ amplitude improves metabolic outcomes in circadian-disrupted models, providing mechanistic insight into the relationship between sleep-wake cycles, cellular metabolism, and NAD+ biology.
CD38 is an ecto-enzyme expressed on immune cells and vascular tissue that hydrolyzes NAD+ to ADPR and nicotinamide, contributing significantly to NAD+ turnover in tissues with high immune cell infiltration. CD38 expression increases with age and in inflammatory states — a pattern that researchers have proposed as a key driver of age-related NAD+ decline beyond the biosynthetic capacity reduction attributed to NAMPT downregulation.
Research has examined CD38-NAD+ axis interactions in the context of chronic inflammatory conditions, finding that elevated CD38 activity in aged tissues correlates with reduced NAD+ concentrations and impaired SIRT1/SIRT3 activity. Studies using CD38 inhibitors alongside NAD+ precursors have explored additive NAD+ restoration effects, contributing to understanding of which NAD+ depletion mechanism dominates in different tissue and disease contexts.
The NAD+/sirtuin axis intersects with virtually every established hallmark of aging: genomic instability (through SIRT1 and SIRT6-mediated DNA repair), telomere attrition (through SIRT1 interaction with telomere-binding proteins), epigenetic alterations (through sirtuin deacetylation of histones and transcription factors), loss of proteostasis (through SIRT2’s role in protein aggregation prevention), mitochondrial dysfunction (through SIRT3/SIRT4/SIRT5 metabolic enzyme regulation), cellular senescence (through SIRT1’s regulation of p53 and NF-κB), and stem cell exhaustion (through NAD+-dependent regulation of stem cell self-renewal pathways).
This remarkable breadth of biological connections explains why NAD+ research has attracted such widespread scientific interest across aging biology, metabolic disease, neurodegenerative disease, and oncology. No other single metabolite intervention has demonstrated as many mechanistic connections to established aging pathways — positioning NAD+ research at the intersection of some of the most important questions in contemporary biomedical science.
Hygroscopicity and oxidation: NAD+ is highly hygroscopic and rapidly absorbs moisture from the air, which drives hydrolysis to AMP and nicotinamide mononucleotide. Store under nitrogen or argon atmosphere in sealed containers with desiccant. Minimize air exposure during handling — weigh and dissolve quickly, working in dry conditions where possible.
Solution stability: NAD+ in aqueous solution undergoes spontaneous hydrolysis and non-enzymatic oxidation-reduction reactions. Prepare stock solutions fresh immediately before use or on the day of the experiment. If storage of working solutions is necessary, use neutral to slightly acidic pH (6.5–7.0), store at 4°C in the dark, and verify concentration by absorbance at 260 nm before use.
Distinguishing NAD+ from NADH in assays: Research using fluorometric or colorimetric NAD+/NADH assays must carefully distinguish the oxidized and reduced forms. Enzymatic cycling assays provide the most sensitive and specific quantification of each form in cellular and tissue extracts — standard UV absorbance measurements at 340 nm measure total reduced form (NADH) but require calculation to determine the NAD+/NADH ratio.
Official Peptides supplies research-grade NAD+ at ≥98% purity verified by HPLC, in 500mg quantities suitable for cell culture, biochemical assay, and in vivo research applications. Each batch is independently verified for identity and purity. We ship with cold pack to minimize thermal exposure during transit and recommend cold storage immediately upon receipt.
Order NAD+ from Official Peptides →
Official Peptides supplies research-grade NAD+ (500mg per vial) with >99% HPLC purity and batch-specific COA included. US domestic shipping 2–5 business days. For in vitro research use only.
All content is provided for research reference purposes only. For in vitro laboratory research use only.